The effect of levosimendan in rat mesenteric ischemia/reperfusion injury

Journal of Investigative Surgery

Volumn 26, Issue 6, 2013, Pages 325-333

  Polat, Beyzagul ^a   Albayrak, Abdulmecit ^b   Halici, Zekai ^b   Karakus, Emre ^a   Bayir, Yasin ^a   Demirci, Elif ^b   Cadirci, Elif ^a   Odaci, Ersan ^c   Yayla, Muhammed ^b   Atamanalp, Sabri Selcuk ^b  

^a ATATÜRK UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Cytokines; Ischemia reperfusion; Levosimendan; Rat

Indexed keywords

GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVOSIMENDAN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INTESTINE; MESENTERIC ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; HYDRAZONES; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINES; NF-KAPPA B; PYRIDAZINES; RATS; REPERFUSION INJURY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887932975     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2013.806615     Document Type: Article

References (50)

1. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: A review. Acta Cir Bras. 2005;20:336-343
2. Vinardi S, Pierro A, Parkinson EJ, et al. Hypothermia throughout intestinal ischaemia-reperfusion injury attenuates lung neutrophil infiltration. J Pediatr Surg. 2003;38:88-91; discussion 88-91
3. Parks DA, Granger DN. Contributions of ischemia and reperfusion to mucosal lesion formation. Am J Physiol. 1986;250:G749-G753
4. Rudiger HA, Clavien PA. Tumor necrosis factor alpha, but not Fas, mediates hepatocellular apoptosis in the murine ischemic liver. Gastroenterology. 2002;122:202-210
5. Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195-S199
6. Koksoy C, Kuzu MA, Ergun H, et al. Intestinal ischemia and reperfusion impairs vasomotor functions of pulmonary vascular bed. Ann Surg. 2000;231:105-111
7. Innes CA, Wagstaff AJ. Levosimendan: A review of its use in the management of acute decompensated heart failure. Drugs. 2003;63:2651-2671
8. Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11
9. Revermann M, Schloss M, Mieth A, et al. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med. 2011;37:1368-1377
10. Hasslacher J, Bijuklic K, Bertocchi C, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study. Crit Care. 2011;15:R166
11. Parissis JT, Andreadou I, Markantonis SL, et al. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis. 2007;195:e210-e215
12. Megison SM, Horton JW, Chao H, et al. A new model for intestinal ischemia in the rat. J Surg Res. 1990;49:168-173
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408
14. Park PO, Haglund U, Bulkley GB, et al. The sequence of development of intestinal tissue injury after strangulation ischemia and reperfusion. Surgery. 1990;107:574-580
15. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol. 2000;190:255-266
16. Yao YM, Sheng ZY, Yu Y, et al. The potential etiologic role of tumor necrosis factor in mediating multiple organ dysfunction in rats following intestinal ischemia-reperfusion injury. Resuscitation. 1995;29:157-168
17. Yamada T, Murase N, Maeda T, et al. Protective effect of TNF-alpha and IL-1 beta inhibitor FR167653 on ischemiareperfusion injury in rat small intestinal transplantation. Transplant Proc. 1998;30:2638
18. Sun Z,Wang X, Lasson A, et al. Roles of platelet-activating factor, interleukin-1beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion. J Surg Res. 1999;87:90-100
19. Nezu Y, Shigihara K, Harada Y, et al. Effects of small intestinal ischemia and reperfusion on expression of tumor necrosis factor-alpha and interleukin-6 messenger RNAs in the jejunum, liver, and lungs of dogs. Am J Vet Res. 2008;69:512-518
20. Brandt LJ, Boley SJ. Sleinsenger and Fordtran's gastrointestinal and liver disease. Intestinal ischemia. Philadelphia, IL: Feldman M, Friedman IS, Sleisenger MH. Saunders. 2002:2321-2340
21. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology. 2001;94:1133-1138
22. Saugstad OD. Hypoxanthine as an indicator of hypoxia: Its role in health and disease through free radical production. Pediatr Res. 1988;23:143-150
23. Tsuruma T, Yagihashi A, Matsuno T, et al. The heat-shock protein 70 family reduces ischemia/reperfusion injury in small intestine. Transplant Proc. 1996;28:2629-2630
24. Nezu Y, Tagawa M, Sakaue Y, et al. Kinetics of endotoxin concentration and tumor necrosis factor-alpha, interleukin- 1beta, and interleukin-6 activities in the systemic and portal circulation during small intestinal ischemia and reperfusion in dogs. Am J Vet Res. 2002;63:1680-1686
25. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet. 2002;360:196-202
26. Sorsa T, Pollesello P, Permi P, et al. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol. 2003;35:1055- 1061
27. Boknik P, Neumann J, Kaspareit G, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther. 1997;280:277-283
28. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147
29. Brixius K, Reicke S, Schwinger RH. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol. 2002;282:H131-H137
30. Malmberg M, Vahasilta T, Saraste A, et al. Intracoronary levosimendan during ischemia prevents myocardial apoptosis. Front Physiol. 2012;3:17
31. Yasa H, Yakut N, Emrecan B, et al. Protective effects of levosimendan and iloprost on lung injury induced by limb ischemia-reperfusion: A rabbit model. J Surg Res. 2008;147:138-142
32. Katircioglu SF, Seren M, Parlar AI, et al. Levosimendan effect on spinal cord ischemia-reperfusion injury following aortic clamping. J Card Surg. 2008;23:44-48
33. Takizawa Y, Kishimoto H, Kitazato T, et al. Changes in the localization of ileal P-glycoprotein induced by intestinal ischemia/ reperfusion. Biol Pharm Bull. 2011;34:408-414
34. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001;38:307-314
35. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell. 1995;81:479-482
36. Lee JI, Burckart GJ.Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol. 1998;38:981-993
37. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem. 1999;274:27339-27342
38. Albayrak Y, Halici Z, Odabasoglu F, et al. The effects of testosterone on intestinal ischemia/reperfusion in rats. J Invest Surg 2011; 24:283-291
39. Oral A, Odabasoglu F, Halici Z, et al. Protective effects of montelukast on ischemia-reperfusion injury in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation. Fertil Steril. 2011;95:1360-1366
40. Cadirci E,OralA,Odabasoglu F, et al. Atorvastatin reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation. Naunyn Schmiedebergs Arch Pharmacol. 2010;381:455-466
41. Halici Z, Karaca M, Keles ON, et al. Protective effects of amlodipine on ischemia-reperfusion injury of rat ovary: biochemical and histopathologic evaluation. Fertil Steril. 2008;90:2408-2415
42. Kruidenier L, vanMeeteren ME, Kuiper I, et al. Attenuated mild colonic inflammation and improved survival fromsevere DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic Biol Med. 2003;34:753-765
43. Oktar BK, Gulpinar MA, Bozkurt A, et al. Endothelin receptor blockers reduce I/R-induced intestinal mucosal injury: Role of blood flow. Am J Physiol Gastrointest Liver Physiol. 2002;282:G647-G655
44. Seyhan N, Canseven AG. In vivo effects of ELF MFs on collagen synthesis, free radical processes, natural antioxidant system, respiratory burst system, immune system activities, and electrolytes in the skin, plasma, spleen, lung, kidney, and brain tissues. Electromagn Biol Med. 2006;25:291-305
45. Suzer T, Coskun E, Demir S, et al. Lipid peroxidation and glutathione levels after cortical injection of ferric chloride in rats: Effect of trimetazidine and deferoxamine. Res Exp Med (Berl). 2000;199:223-229
46. Paller MS, Patten M. Protective effects of glutathione, glycine, or alanine in an in vitro model of renal anoxia. J Am Soc Nephrol. 1992;2:1338-1344
47. Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299-1321
48. Yigiter M, Halici Z, Odabasoglu F, et al. Growth hormone reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation. Eur J Obstet Gynecol Reprod Biol. 2011;157:94-100
49. Sakamoto M, Takaki E, Yamashita K, et al. Nonenzymatic derived lipid peroxide, 8-iso-PGF2 alpha, participates in the pathogenesis of delayed cerebral vasospasm in a canine SAH model. Neurol Res. 2002;24:301-306
50. Basu S, Hellberg A, Ulus AT, et al. Biomarkers of free radical injury during spinal cord ischemia. FEBS Lett. 2001;508:36-38